Flagship explainer
What drives ALNYLAM PHARMACEUTICALS, INC.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $314M | FY2025 |
| |
| Income before tax | $323M | FY2025 |
|
| Operating income | $502M | FY2025 |
|
| $3.7B | FY2025 |
| |
| Ending assets | $5.0B | FY2025 |
|
| Beginning assets | $4.2B | FY2024 |
|
| $789M | FY2025 |
| |
| $67.1M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001628280-26-007497